Welcome to the UPF Digital Repository

Development and validation of combined symptom-medication scores for allergic rhinitis

Show simple item record

dc.contributor.author Sousa Pinto, Bernardo
dc.contributor.author Antó i Boqué, Josep Maria
dc.contributor.author Bousquet, Jean
dc.date.accessioned 2022-02-11T07:07:11Z
dc.date.available 2022-02-11T07:07:11Z
dc.date.issued 2022
dc.identifier.citation Sousa-Pinto B, Azevedo LF, Jutel M, Agache I, Canonica GW, Czarlewski W et al. Development and validation of combined symptom-medication scores for allergic rhinitis. Allergy. 2022 Jul;77(7):2147-62. DOI: 10.1111/all.15199
dc.identifier.issn 0105-4538
dc.identifier.uri http://hdl.handle.net/10230/52469
dc.description.abstract Background: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air® app to generate and validate hypothesis- and data-driven CSMSs. Methods: We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air® , and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). Results: We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartof Allergy. 2022 Jul;77(7):2147-62
dc.rights © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.title Development and validation of combined symptom-medication scores for allergic rhinitis
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1111/all.15199
dc.subject.keyword Medication score
dc.subject.keyword Quality-of-life
dc.subject.keyword Rhinitis
dc.subject.keyword Symptom score
dc.subject.keyword Work
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking